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Abstract Background Although efficacious in stroke pre-
vention in non-valvular atrial fibrillation, many warfarin
patients are sub-optimally managed. Objective To evaluate the
association of international normalized ratio control and clin-
ical outcomes among new warfarin patients with non-valvular
atrial fibrillation. Setting Adult non-valvular atrial fibrillation
patients (C18 years) initiating warfarin treatment were selec-
ted from the US Veterans Health Administration dataset
between 10/2007 and 9/2012. Method Valid international
normalized ratio values were examined from the warfarin
initiation date through the earlier of the first clinical outcome,
end of warfarin exposure or death. Each patient contributed
multiple in-range and out-of-range time periods. Main out-
come measure The relative risk ratios of clinical outcomes
associated with international normalized ratio control were
estimated. Results 34,346 patients were included for analysis.
During the warfarin exposure period, the incidence of events
per 100 person-years was highest when patients had interna-
tional normalized ratio\2:13.66 for acute coronary syndrome;
10.30 for ischemic stroke; 2.93 for transient ischemic attack;
1.81 for systemic embolism; and 4.55 for major bleeding.
Poisson regression confirmed that during periods with inter-
national normalized ratio\2, patients were at increased risk of
developing acute coronary syndrome (relative risk ratio: 7.9;
95 % confidence interval 6.9–9.1), ischemic stroke (relative
risk ratio: 7.6; 95 % confidence interval 6.5–8.9), transient
ischemic attack (relative risk ratio: 8.2; 95 % confidence
interval 6.1–11.2), systemic embolism (relative risk ratio: 6.3;
95 % confidence interval 4.4–8.9) and major bleeding (relative
risk ratio: 2.6; 95 % confidence interval 2.2–3.0). During time
periods with international normalized ratio [3, patients had
significantly increased risk of major bleeding (relative risk
ratio: 1.5; 95 % confidence interval 1.2–2.0). Conclusion In a
Veterans Health Administration non-valvular atrial fibrillation
population, exposure to out-of-range international normalized
ratio values was associated with significantly increased risk of
adverse clinical outcomes.
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Impacts on practice
• Non-valvular atrial fibrillation patients exposed to a
warfarin international normalized ratio of less than two
have significantly increased thrombosis risk.
• The adverse event risk was greater for non-valvular
atrial fibrillation patients with below-range interna-
tional normalized ratio than those with above-range
international normalized ratio. Awareness of this excess
risk may better inform clinicians regarding appropriate
therapeutic approach options.
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Introduction
Atrial fibrillation (AF) is the most common heart dys-
rhythmia in the United States. The American Heart Asso-
ciation estimated that 2.7 million Americans are diagnosed
with AF [1]. AF prevalence has increased as the US pop-
ulation has aged, and is expected to continue to rise in the
coming decades [2].
Patients with AF have an almost five-fold increase in the
risk of stroke when compared to those without AF [3].
Current guidelines recommend long-term anticoagulation
treatment for the prevention of stroke among moderate-
and high-risk AF patients [4]. Several large-scale clinical
trials have shown the effectiveness of warfarin in reducing
stroke associated with AF [5–7]. A meta-analysis con-
ducted by Hart et al. [8] in 1999 demonstrated that adjus-
ted-dose warfarin reduced ischemic stroke by 65 % in AF
patients. To maximize benefits and minimize complica-
tions of prophylaxis, warfarin dosing should be closely
monitored and adjusted to maintain the international nor-
malized ratio (INR) [9] between 2.0 and 3.0 for non-val-
vular (NV) AF patients [10].
Aim of the study
Few studies have focused on the effect of out-of-range INR
on important major adverse cardiac outcomes such as acute
coronary syndrome (ACS) and transient ischemic attack
(TIA), in addition to stroke and bleeding. This study
explored the association of INR control and clinical out-
comes among NVAF patients who newly initiated warfarin
prophylaxis.
Ethical approval
No patient identity or medical records were disclosed for
the purposes of this study, except in compliance with
applicable law. Since the core study proposed herein does
not involve the collection, use, or transmittal of individual
identifiable data, Institutional Review Board (IRB)
approval to conduct this study is not required. Both the data
set and the security of our offices where we keep the data
set meet the requirements of the Health Insurance Porta-
bility and Accountability Act (HIPAA) of 1996.
Methods
This study report was written in compliance with the
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) statement [11].
Data source
The Veterans Health Administration (VHA) dataset was
used to access medical, pharmacy, laboratory and enroll-
ment information. The VHA is the largest integrated health
care system in the United States, providing care for 5
million patients across the country [12]. Electronic health
data collected within the VA national Medical SAS
Dataset and Decision Support System were evaluated.
These data include hospital and outpatient diagnoses,
procedures, laboratory results and dispensed medications.
Death date was determined using the VA Vital Status file,
which ascertains mortality using the Social Security Death
Master File, Medicare Vital Status Files, and VA Benefi-
ciary Identification and Records Locator Subsystem.
Study population
The study population consisted of patients aged 18 years or
older with at least one pharmacy claim for warfarin from
October 1, 2008 to September 30 2011. Only incident
warfarin users were included for study; prevalent warfarin
users were excluded. Study patients were required to have
at least one valid INR measurement (0.5 B INR B 20)
within 14 days after the initial warfarin pharmacy claim
date (index date) and at least three INR measurements.
Included patients must have had continuous health care
coverage for 12 months prior to the index date, the period
that would serve as the baseline period.
The population was further restricted to patients with at
least one medical claim for AF [International Classification
of Diseases, 9th revision, Clinical Modification (ICD-9-
CM) code 427.31] between 30 days before the index date
through the end of the follow-up period. Patients with at
least one pharmacy claim for warfarin during the baseline
period and those diagnosed with transient or perioperative
AF disease, mitral or aortic valve repair or replacement, at
least two claims for hyperthyroidism, record of pregnancy
or delivery at any time during the study period were
excluded.
Study Measures
The warfarin exposure time during the follow-up period was
estimated based on an algorithm commonly used in AF
studies by Go et al. [13]. Warfarin exposure duration corre-
sponded to the prescription date plus days’ supply and
45 days. INR coverage was assumed to be 45 days after the
INR measurement date. If a patient had a gap [45 days
between two consecutive warfarin exposure periods, therapy
was considered discontinued before the gap. For patients
who restarted warfarin therapy after discontinuation, only
the first warfarin exposure period was considered.
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INR results were observed from the index date through
the earlier of the first clinical outcome, end of warfarin
exposure or death. Simple linear interpolation [14] was
applied to classify each day of follow-up in predefined
therapeutic range categories (INR \2, INR 2–3, INR [3,
INR unknown). For each patient, periods of INR values of
in-range (2–3) and out-of-range (\2 and [3) were recor-
ded. The period without INR test results was classified as
‘‘unknown’’. Clinical outcomes including the first inpatient
occurrence of thromboembolic events (ACS, ischemic
stroke, TIA, systemic embolism) and major bleeding were
observed during the same follow-up period.
Data Analyses
Baseline characteristics including demographic and clinical
characteristics were summarized with descriptive analyses.
The number of patients with clinical outcomes and event
rates per 100 patient-years of each INR range were
calculated.
The relationship between clinical outcomes and out-of-
range INR values was estimated using the multivariate
Poisson regression model to control for differences in
patient age, gender, region, race, Charlson Comorbidity
Index (CCI) score, baseline treatment and individual
comorbidities. Poisson regression was applied to adjust for
repeated measures and is more appropriate for INR mea-
sures since it is a count model. Relative risk ratios (RRRs)
and 95 % confidence intervals (CIs) are reported, by
comparing the risk during the time periods when INR was
in-range versus when INR was out-of-range. An additional
analysis was performed replicating the clinical outcome
Poisson regression during the first 6 months and after
6 months of warfarin initiation.
Results
The study population included 34,346 patients diagnosed
with NVAF who initiated warfarin prophylaxis. Table 1
shows the baseline characteristics of these patients. The
mean age of NVAF patients receiving initial warfarin
prescriptions was 71 years, and 98.36 % were male. Most
patients were White (69.53 %) and resided in the South US
region (34.61 %). Hypertension (75.87 %) was the most
common comorbidity followed by diabetes mellitus
(39.53 %) and vascular disease (39.02 %). Based on
CHADS2 risk scoring [15, 16], 89.34 % patients were at
moderate or high-risk of stroke.
There were 1,372 ACS events, 1,045 ischemic strokes,
297 TIA events, 189 systemic emboli and 726 major
bleeding events that required hospitalization observed
during the warfarin exposure period. Table 2 provides
incidence rates per 100 person-years for each of the clinical
outcomes. All event rates were highest when patients had
INR \2, even for major bleeding.
The association between clinical outcomes and out-of-
range INR is presented in Fig. 1, including respective rel-
ative risk estimates and CIs. After controlling for patient
characteristics, during time periods with INR\2 exposure,
patients had significantly increased risk of developing ACS
(RRR = 7.89, 95 % CI = 6.85–9.08) compared to those
with INR values between 2 and 3. Similarly, during time
periods with INR\2, patients were found to be associated
with significantly increased risk of developing ischemic
stroke (RRR = 7.60, 95 % CI = 6.50–8.89), TIA
(RRR = 8.24, 95 % CI = 6.08–11.18), systemic embo-
lism (RRR = 6.27, 95 % CI = 4.40–8.92) and major
bleeding (RRR = 2.58, 95 % CI = 2.19–3.03), compared
to periods with INR of 2–3. During time periods with INR
[3, patients were found to be associated with significantly
higher risk of major bleeding (RRR = 1.55, 95 %
CI = 1.21–1.97) than those with INR of 2–3. During time
periods with INR [3, patients were associated with sig-
nificantly decreased risk (RRR = 0.56, 95 %
CI = 0.37–0.85) of developing ischemic stroke compared
to those with INR of 2–3.
To examine the association between out-of-range INR
and adverse clinical outcomes over time, Poisson regres-
sion was performed to compare the periods before and after
the first 6 months of warfarin exposure (Table 3). For the
period of exposure to INR \2, the significantly increased
risks for adverse clinical events were consistent before and
after 6 months of warfarin use for all clinical outcomes,
except for TIA. For TIA, the RRR diminished after
6 months of warfarin use, and was not statistically signif-
icant. For thromboembolic events, the magnitudes of the
RRRs were higher during the first 6 months compared to
that after 6 months. Conversely, for major bleeding, the
RRR was higher after 6 months. For the period of exposure
to INR [3, the difference was less obvious between the
periods before and after 6 months. There was a slight
increase in the risk of major bleeding during the first
6 months of warfarin use; this increased risk remained after
6 months, although it was no longer statistically
significant.
Discussion
Using national VHA data, this study assessed the rela-
tionship between out-of-range INR values and clinical
outcomes among 34,346 NVAF patients who were newly
prescribed warfarin prophylaxis. The risks of thromboem-
bolic events were 6.3–8.2 times higher during periods when
patients had INR \2, compared to periods with an INR of
Int J Clin Pharm (2015) 37:53–59 55
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2–3. Conversely, risk of a bleeding event was 1.5–2.6 times
higher when INR was outside of the 2–3 range, as com-
pared to when INR was within that range. The study con-
firmed previous results [17], while demonstrating the
particularly high magnitude of risks associated with below-
range INRs. Thromboembolic risk was also heightened
during the first 6 months of warfarin therapy when patients
were exposed to below-range INR values.
The current study results were consistent with a number
of studies that have shown an association between supra-
therapeutic INR (INR [3) and increased bleeding rates
among patients prescribed warfarin. Hylek et al. [18] found
a nine times higher odds of intracranial bleeding among
patients with INR higher than 4.5 at the time of a stroke.
Table 1 Baseline demographic and clinical characteristics of war-






Age (Mean) 70.98 10.22
Age 18–64 10,938 31.85 %
Age 65–74 9,608 27.97 %
Age 75? 13,800 40.18 %
Gender
Male 33,783 98.36 %
Female 563 1.64 %
US geographic location
Northeast 4,988 14.52 %
Midwest 8,612 25.07 %
South 11,914 34.69 %
West 7,078 20.61 %
Other 1,754 5.11 %
Race
Black 2,673 7.78 %
Hispanic 1,092 3.18 %
White 23,882 69.53 %
Other 6,699 19.50 %
Baseline comorbid condition
Indices
Charlson comorbidity index score 1.98 2.03
Chronic disease score 7.68 4.50
CHADS2 score
Low (0) 3,662 10.66 %
Moderate (1) 9,154 26.65 %
High ([1) 21,530 62.69 %
CHADS2-VASc Score
Low (0) 1,976 5.75 %
Moderate (1) 4,192 12.21 %
High ([1) 28,178 82.04 %
ATRIA score
Low (0–3) 27,279 79.42 %
Moderate (4) 2,451 7.14 %
High (5–10) 4,616 13.44 %
Comorbidities
Congestive heart failure 6,962 20.27 %
Diabetes mellitus 13,577 39.53 %
Hypertension 26,060 75.87 %
Ischemic stroke 1,652 4.81 %
Transient ischemic attack 819 2.38 %
Vascular disease 13,403 39.02 %
End-stage renal disease 391 1.14 %
Hospitalized hemorrhagic stroke 1 0.00 %






Chronic obstructive pulmonary disease 1,667 4.85 %
Anemia 4,714 13.73 %
Hospitalized major bleeding 153 0.45 %
Bleeding disorder 572 1.67 %
Baseline medications
Rate control medication use 22,430 65.31 %
Rhythm control medication use 2,612 7.60 %
Aspirin use 10,351 30.14 %
NVAF, non-valvular atrial fibrillation; SD, standard deviation;
CHADS2 score, congestive heart failure (point = 1); Hypertension
(point = 1), Age C 75 years (point = 1), Diabetes mellitus
(point = 1), prior Stroke or transient ischemic attack (point = 2);
CHADS2-VASc score
16, congestive heart failure (point = 1);
Hypertension (point = 1), Age C 75 years (point = 2), Diabetes
mellitus (point = 1), prior Stroke or transient ischemic attack
(point = 2); Vascular disease (point = 1), Age 65–74 year-
s(point = 1), Female category (point = 1); ATRIA, anticoagulation
and risk factors in atrial fibrillation bleeding risk score (factors:
anemia, severe renal disease, age C 75 years, previous hemorrhage,
diagnosed hypertension)
Table 2 Incidence rates by INR range
Incidence per 100 patient-years
INR \2 INR 2–3 INR [3
Ischemic stroke 10.3 1.3 0.72
TIA 2.9 0.33 0.23
Systemic embolism 1.8 0.26 0.12
ACS 13.7 1.6 1.5
Major bleeding 4.6 1.6 2.6
INR international normalized ratio, TIA transient ischemic attack,
ACS acute coronary syndrome
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Sarawate et al. [19] found a 1.72 higher adjusted odds of
major hemorrhage among AF patients who had an INR of
[3 upon hospital admission. Tapson et al. [20] observed
that 9 % of patients with or at risk for thromboembolic
diseases had INR[4 during a hospitalization, and 0.8 % of
patient experienced major hemorrhage, although this study
did not correlate high INR with bleeding events. In addi-
tion, the current study showed the increased risk of
bleeding during outpatient exposure to supra-therapeutic
INR.
Conversely, sub-therapeutic INR (INR\2) increases the
risk of developing thromboembolic complications. In a
large cohort study of 13,559 NVAF patients, those with
INR values \2.0 showed an increased risk of stroke com-
pared with those whose INR was within the therapeutic
range (p = 0.03) [18]. A systematic review of 47 studies
showed that a 12 % improvement in target therapeutic
range prevents one thromboembolic event per 100 patient-
years [21]. The current study adds to the previous literature
by quantifying the magnitude of the increased risks when
patients were exposed to below-range INR.
Surprisingly, in this population, sub-therapeutic INR
was associated with bleeding events. This may indicate
downward adjustments of warfarin dosing in response to
the bleeding event. Because the Rosendaal method inter-
polates INR levels between two INR values, the analysis
could not determine the actual INR value on the bleeding
event date. This limitation of the Rosendaal method means
that the RRR estimates of the current analysis may be an
underestimation, as clinicians may have made corrective
adjustments to the warfarin dose in response to thrombo-
embolic or bleeding events. The Rosendaal method is the
proven standard method for this type of analysis. To our
knowledge, prior research studies have not compared
bleeding risk among patients with warfarin INR \2 to
those with in-range INR. A recently published meta-ana-
lysis conducted by Mearns et al. [22] showed that only
Fig. 1 Adjusted RRRs for clinical outcomes, out-of-range versus in-
range. RRR relative risk ratio, INR international normalized ratio, TIA
transient ischemic attack, ACS acute coronary syndrome; Syst Emb
systematic embolism. Note: A relative risk ratio of higher than 1
indicates a higher likelihood of having the clinical outcomes as
compared to in-range international normalized ratio time periods. The
horizontal bars for each relative risk ratio correspond to the 95 %
confidence intervals. If the 95 % confidence interval exclude 1, the
relative risk ratio estimate is statistically significant
Table 3 Relative risk estimates for clinical outcomes during and
after the first 6 months of warfarin exposure
Clinical outcomes
INR Before 6 months After 6 months
Relative risk p-value Relative risk p-value
ACS
\2 6.6505 \0.0001 4.3918 \0.0001
[3 0.8847 0.4645 0.7998 0.5357
Ischemic stroke
\2 6.8189 \0.0001 2.9368 \0.0001
[3 0.5362 0.0090 0.4596 0.0967
Transient ischemic attack
\2 8.9904 \0.0001 1.8577 0.0768
[3 0.8693 0.7378 0.2505 0.1769
Systemic embolism
\2 4.8545 \0.0001 4.5573 0.0067
[3 0.2138 0.0338 1.8882 0.4476
Major bleeding
\2 2.0007 \0.0001 3.0921 \0.0001
[3 1.4562 0.0120 1.5150 0.0555
INR 2–3 = Reference group
ACS acute coronary syndrome, INR international normalized ratio
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42 % of hemorrhagic events occurred among patients
exposed to warfarin INR at[3.0, indicating that more than
half of the bleeding events occurred when INR was \3.0.
Our findings provide the hypothesis: when INR is\2.0, the
bleeding risk may be higher than when INR is within the
2.0–3.0 range. Future research is warranted to investigate
and confirm our findings.
The current study was subject to several limitations.
While claims data are valuable for the examination of health
outcomes, treatment patterns, and costs, claims data are
collected for the purpose of payment and not research. The
presence of a claim for a filled prescription does not indicate
that the medication was consumed or that it was taken as
prescribed. In the current analysis, the presence of INR
testing and refill data of warfarin increased the certainty that
warfarin was indeed consumed. In addition, diagnostic codes
in claims data may contain inaccuracies or omissions. These
inaccuracies are expected to occur randomly, however, and
are unlikely to have significantly impacted the findings.
Finally, a general limitation of claims data analysis is that
only observable factors were used, and there may be residual
confounding due to unmeasured clinical and disease-specific
parameters. Despite these limitations, the large population
and extended follow-up allowed the observation of clinical
impact of exposure to sub-optimal INR level.
The results obtained using the VHA claims database may
not be generalizable to other populations with NVAF.
Importantly, the VHA population contains very few women,
and veterans may have additional or different risk factors as
compared to the general population. The conclusions drawn
from this study should be cautiously interpreted, and addi-
tional data from other populations is needed.
Conclusion
In this large VHA population, NVAF patients newly pre-
scribed warfarin for stroke prophylaxis had significantly
higher risk of adverse clinical outcomes, including ACS
and TIA, during periods of exposure to out-of-range INR
values. The risks of thromboembolic events associated with
below-range INR were especially high, indicating sub-
stantial danger to patients when warfarin prophylaxis doses
are subtherapeutic.
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